Uncategorized

December 13, 2021

How to freeze-dry a potential COVID-19 vaccine

BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the microbe responsible for the coronavirus disease 2019 (COVID-19), through the development of a thermostable recombinant nanoparticle vaccine.
December 13, 2021
Coronavirus cells in microscopic view. Virus

POP Biotechnologies announces formation of joint venture, EUPOP Life Sciences, in collaboration with South Korean collaborator, Eubiologics, Co., Ltd.

POP Biotechnologies announces formation of joint venture, EUPOP Life Sciences, in collaboration with South Korean collaborator, Eubiologics, Co., Ltd. POP Biotechnologies (POP BIO) is pleased to […]
October 8, 2021

POP BIO awarded $599,981 Phase 1 SBIR Award to Develop Thermostable COVID-19 Vaccine

BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the microbe responsible for the coronavirus disease 2019 (COVID-19), through the development of a thermostable recombinant nanoparticle vaccine.
February 23, 2021

COVID-19 vaccine developed by UB startup approved for human trials

EuCorVac-19, a next-generation particle-based COVID-19 vaccine incorporating POP BIO's SNAP technology has gained regulatory approval for Phase I/II studies